Recent Investment Analysts’ Ratings Updates for Gilead Sciences (GILD)

Gilead Sciences (NASDAQ: GILD) has recently received a number of price target changes and ratings updates:

• 3/11/2025 – Gilead Sciences had its price target raised by analysts at Morgan Stanley from $123.00 to $130.00. They now have an “overweight” rating on the stock.
• 3/5/2025 – Gilead Sciences had its price target raised by analysts at Wells Fargo & Company from $120.00 to $140.00. They now have an “overweight” rating on the stock.
• 3/5/2025 – Gilead Sciences had its price target raised by analysts at Bank of America Co. from $116.00 to $126.00. They now have a “buy” rating on the stock.
• 3/4/2025 – Gilead Sciences had its price target raised by analysts at Oppenheimer Holdings Inc. from $115.00 to $132.00. They now have an “outperform” rating on the stock.
• 2/18/2025 – Gilead Sciences was upgraded by analysts at Deutsche Bank Aktiengesellschaft from a “hold” rating to a “buy” rating. They now have a $120.00 price target on the stock, up previously from $80.00.
• 2/13/2025 – Gilead Sciences was upgraded by analysts at DZ Bank AG from a “hold” rating to a “buy” rating. They now have a $108.00 price target on the stock.
• 2/12/2025 – Gilead Sciences had its price target raised by analysts at Royal Bank of Canada from $84.00 to $90.00. They now have a “sector perform” rating on the stock.
• 2/12/2025 – Gilead Sciences had its price target raised by analysts at Wells Fargo & Company from $105.00 to $120.00. They now have an “overweight” rating on the stock.
• 2/12/2025 – Gilead Sciences had its price target raised by analysts at Piper Sandler from $105.00 to $110.00. They now have an “overweight” rating on the stock.
• 2/12/2025 – Gilead Sciences had its price target raised by analysts at Morgan Stanley from $113.00 to $123.00. They now have an “overweight” rating on the stock.
• 2/12/2025 – Gilead Sciences had its price target raised by analysts at BMO Capital Markets from $110.00 to $115.00. They now have an “outperform” rating on the stock.
• 2/12/2025 – Gilead Sciences had its price target raised by analysts at The Goldman Sachs Group, Inc. from $85.00 to $96.00. They now have a “neutral” rating on the stock.
• 2/12/2025 – Gilead Sciences had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 2/3/2025 – Gilead Sciences had its “sector perform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $84.00 price target on the stock.
• 1/29/2025 – Gilead Sciences had its price target raised by analysts at JPMorgan Chase & Co. from $105.00 to $115.00. They now have an “overweight” rating on the stock.

Gilead Sciences Stock Performance

GILD opened at $111.44 on Monday. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The company has a fifty day moving average of $101.82 and a 200 day moving average of $92.92. The stock has a market capitalization of $138.78 billion, a price-to-earnings ratio of 301.19, a PEG ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be issued a dividend of $0.79 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a yield of 2.84%. Gilead Sciences’s dividend payout ratio (DPR) is presently 854.05%.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now owns 129,873 shares of the company’s stock, valued at $11,863,898.55. The trade was a 1.89 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 302,785 shares of company stock worth $30,503,250 in the last 90 days. 0.16% of the stock is owned by corporate insiders.

Institutional Trading of Gilead Sciences

Several large investors have recently bought and sold shares of GILD. Norges Bank acquired a new stake in Gilead Sciences during the 4th quarter valued at approximately $1,789,254,000. FMR LLC lifted its stake in Gilead Sciences by 79.4% during the 3rd quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock valued at $2,780,329,000 after acquiring an additional 14,680,161 shares during the period. Wellington Management Group LLP lifted its stake in Gilead Sciences by 50.9% during the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock valued at $2,900,921,000 after acquiring an additional 11,665,593 shares during the period. Pacer Advisors Inc. lifted its stake in Gilead Sciences by 723.3% during the 4th quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company’s stock valued at $594,370,000 after acquiring an additional 5,653,075 shares during the period. Finally, Northern Trust Corp lifted its stake in shares of Gilead Sciences by 19.7% in the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company’s stock valued at $1,377,707,000 after purchasing an additional 2,458,954 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.